TGTX Stock — TG Therapeutics Inc.

TG Therapeutics Inc. (TGTX)

Updated October 16, 2026.

TGTX is a Stock. Its deepest 1-year drawdown was 23.5%.

TG Therapeutics is a commercial-stage biopharmaceutical company focused on developing and commercializing treatments for B-cell mediated diseases, particularly multiple sclerosis and related conditions. The company markets BRIUMVI, an anti-CD20 monoclonal antibody approved for relapsing forms of MS in adults, and maintains a pipeline of investigational medicines including additional MS candidates and oncology-focused therapies. As an equity stock with no established distribution history, it is oriented toward capital appreciation rather than income generation and may appeal to investors seeking exposure to biopharmaceutical development and commercialization.

TGTX performance

Returns are updating. TGTX's total return appears here after the next nightly update.

Its deepest 1-year drawdown was 23.5%.

TGTX key facts

Asset type

Stock

Asset class

Equity

Inception date

12/14/1995

Distribution frequency

None

Last close

$53.97 (as of 2026-10-16)

Market cap

$8,261,920,813

Average volume

1770042.0

Beta

1.799

Payout ratio

0.0%

P/E ratio

19.63

Forward P/E

25.9067

EPS

$2.75

How Dividend Vision calculates yield and returns

Distribution rate (the posted rate) uses calculation basis unavailable. Issuer rates can use a different denominator and date, including ex-date NAV. Trailing-12-month yield is the sum of split-adjusted cash distributions with ex-dates in the last 12 months, divided by the published price. It lags a recent raise or cut. Total return uses split-adjusted close with distributions reinvested on the ex-dividend date (a modeling convention, not the cash-settlement date) from the first stored bar on or after inception through the latest bar, compared with the same window on the benchmark. That is the security's total return, not your personal gain/loss.

Yield and safety methodology · Distribution rate methodology · Distribution Safety Score methodology

Sources and review

Primary sources: prices and distributions from Dividend Vision, derived from vendor EOD data.

Reviewed by Bert Sweet, CEO and Co-owner of Dividend Vision. Methodology: Distribution Safety Score.

TGTX risks and drawbacks

The deepest 1-year drawdown on record here is 23.5%.

Who may consider TGTX — and who may not

It is a weaker fit for investors who need monthly cash flow (TGTX does not currently distribute). This is educational context, not a recommendation to buy or sell.

More on TGTX

• All tickers starting with T

Tagged: Healthcare.

Frequently asked questions